Scientific Program

(as per December 11th, 2018)




14.00 Registration opens
Opening Session chairs afternoon:
Emma Guttman (New York, USA)
Patrick M. Brunner (Vienna, Austria)
16.00 – 16.10 Welcome address
16.10 – 16.35 Setting the stage – Historic perspectives
Georg Stingl (Vienna, Austria)
16.35 – 17.00 Setting the stage – The translational revolution in inflammatory skin
James G. Krueger (New York, NY, USA)
17.00 –17.30 Two sides of Th17 cells in autoimmunity and tissue homeostasis
Vijay Kuchroo (Boston, MA, USA)

Session chairs evening:
Erwin Tschachler (Vienna, Austria)
Luis Puig (Barcelona, Spain)

17.30 – 18.30

Oral presentations from selected abstracts

#125 Selective oral JAK3 and TYK2/JAK1 kinase inhibitors both
demonstrate significant hair-growth compared to placebo and improvement of hair-associated keratins in patients with moderate-to-severe Alopecia Areata.
Emma Guttman (New York, USA)

#130 A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis.
Ian M. Catlett (Princeton, USA)

#86 A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in patients with moderate-to-severe plaque psoriasis.
Seth Forman (Tampa, USA)

#123 New innovative approach combining comparative transcriptomics from three unique psoriasis models to identify predictive PsA biomarkers.
Johann Gudjonsson (Ann Arbor, USA)

#LB4 Guselkumab demonstrates superior long-term responses to secukinumab at Week48 in the treatment of moderate to severe psoriasis: Results from the ECLIPSE trial
Richard Langley (Halifax, Canada)

18.30 – 21.00 Poster viewing and networking




  Session chairs morning:
Sylvia Knapp (Vienna, Austria)
Michael Detmar (Zurich, Switzerland)
08.30 – 9.00 A perspective of dendritic cells in inflammatory skin diseases
Thomas Bieber (Bonn, Germany)
09.00 – 09.30 Resident T cells in health and disease
Rachael Clark (Boston, MA, USA)
09.30 – 10.00 T cell subsets across inflammation and cancer
Thomas S. Kupper (Boston, MA, USA)
10.00 – 10.30 Innate lymphoid cells in health and disease
Graham Ogg (Oxford, United Kingdom)         
10.30 – 10.45 Oral presentations from selected abstracts

#112 Resident T cells trigger disease-associated tissue responses that stratify clinical outcome in human psoriasis.
Liv Eidsmo (Stockholm, Sweden)

10.45 – 11.00 BREAK
11.00 – 12.30 Does Psoriasis Treatment Alter the Risk of Comorbidities? Examining the Evidence
Symposium supported by Eli Lilly

Chair: Kilian Eyerich (Munich, Germany)Psoriasis and Comorbidities: An Overview

Kilian Eyerich (Munich, Germany)

The Role of Cytokines in the Pathogenesis of Psoriasis and Associated Comorbidities
Patrick Brunner (Vienna, Austria)

Does Psoriasis Treatment affect Cardiovascular Disease?
Joel Gelfand (Philadelphia, PA, USA)

Psoriasis and Psyche: What Do We Know?
Kristian Reich (Berlin, Germany)

Panel Discussion and Audience Q&A: Implications for Psoriasis Management
All faculty

Concluding Remarks and Close
Kilian Eyerich (Munich, Germany)

12.30 – 13.00 BREAK

Session chairs afternoon:
Donald Leung (Denver, USA)
Stefanie Eyerich (Munich, Germany)

13.00 – 14.00

Oral presentations from selected abstracts

#138 Blood endotyping distinguishes the profile of vitiligo from other
inflammatory and autoimmune skin diseases.
Tali Czarnowicki (New York, USA)

#102 Low-input RNA sequencing reveals survival program of human skin-resident T cells during complete myeloablation.
Johanna Strobl (Vienna, Austria)

#78 A critical role for IL-37 in regulatory T cell maintenance and CD4+ T cell inhibition.
Mayumi Fujita (Aurora, USA)

#70 KLK6-PAR1 signaling drives psoriasiform manifestations in skin and bone and blockade of PAR1 in explanted psoriasis patient skin decreases key psoriasis transcripts.
Nicole Ward (Cleveland, USA)

14.00 – 14.30 Protective immunity and immunodeficiencies
Jean-Laurent Casanova (New York, NY, USA)
14.30 – 15.30 COFFEE BREAK

Session chairs late afternoon:
Dirk Jan Hijnen (Rotterdam, The Netherlands)
Adelheid Elbe-Bürger (Vienna, Austria)

15.30 – 16.00 Janus kinases in inflammation
Massimo Gadina (Bethesda, MD, USA) on behalf of John O’Shea (Bethesda, MD, USA)
16.00 – 16.30 Visualization of skin inflammation and resulting immunologic concepts
Kenji Kabashima (Kyoto, Japan)
16.30– 17.00 The microbiome and therapeutic implications
Richard Gallo (San Diego, CA, USA)

Oral presentations from selected abstracts

#74 Triple correlation between skin microbiome, skin barrier and immune gene expression pathways in atopic dermatitis.
Claudia Traidl-Hoffmann (Augsburg, Germany)

#45 Baseline inflammatory biomarker profiles and clinical heterogeneity of adult patients with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids.
Brian Nickoloff (Indianapolis, USA)

Official Networking Evening




08.00 – 09.30 Discover the potential: exploring new frontiers of IL-23 inhibitors
Symposium supported by Janssen

Chair: Antonio Costanzo (Milano, Italy) & Kilian Eyerich (Munich, Germany)

Welcome and introduction
Antonio Costanzo (Milano, Italy)

Advancing the science of psoriasis: the underlying pathology and the role IL-23
Antonio Costanzo (Milano, Italy)

New horizons in managing psoriasis:  individualizing care one patient at a time
Kilian Eyerich (Munich, Germany)

Interactive Q&A session
Antonio Costanzo (Milano, Italy) & Kilian Eyerich (Munich, Germany)

Summary and closing
Kilian Eyerich (Munich, Germany)

09.30 – 09.45 BREAK
  Session chairs morning:
Stephan Weidinger (Kiel, Germany)
James T. Elder (Ann Arbor, Michigan)
09.45 – 10.15 How to perform successful clinical trials in inflammatory skin diseases
Kristian Reich (Hamburg, Germany)
10.15 – 10.45 Framing psoriasis
James G. Krueger (New York, NY, USA)         
10.45 – 11.15 Autoantigens in psoriasis
Michel Gilliet (Lausanne, Switzerland)
11.15 – 11.45 Impact of immune targeted therapy on cardiovascular risk: The psoriasis model
Joel Gelfand (Philadelphia, PA, USA)
11.45 – 12.00   BREAK
12.00 – 13.30 THE GREAT DEBATE:
Should the Treatment Paradigm for Mild to Moderate Atopic Dermatitis (AD) Evolve?
Symposium supported by Pfizer

Moderator: Charles Lynde (Ontario, Canada)

Invited Speaker: Aviv Barzilai (Tel Aviv, Israel)

Invited Speaker: Adelaide A. Hebert (Houston,TX, USA)

Invited Speaker: Torsten Zuberbier (Berlin, Germany)

13.30 – 13.45    BREAK
  Session chairs afternoon:
Matthias Schmuth (Innsbruck, Austria)
Zuhair Ballas (Iowa City, USA)
13.45 – 14.15 Inflammatory profile of atopic dermatitis and cytokine targeted treatments
Emma Guttman (New York, NY, USA)
14.15 – 14.45    Barrier defects in atopic dermatitis and prevention strategies
Alan Irvine (Dublin, Ireland)
14.45 – 15.15 Atopic dermatitis at disease onset
Patrick M. Brunner (Vienna, Austria)
15.15 – 15.45 Adopting Orphan Ichthyoses: New Focus for Inflammatory Skin Research
Amy S. Paller (Chicago, IL, USA)
15.45 – 16.15 COFFEE BREAK
  Session chairs late afternoon:
Alain Hovnanian (Paris, France)
Tove Agner (Copenhagen, Denmark)
16.15 – 16.45    Epicutaneous antigen desensitization
Christophe Dupont (Paris, France)
16.45 –17.15 Peripheral tolerance to autoimmune target in pemphigus
Masayuki Amagai (Tokyo, Japan)

Oral presentations from selected abstracts

#48 Conjunctival inflammation and loss of goblet cells in atopic dermatitis patients treated with dupilumab in daily practice. 
Daphne Bakker (Utrecht, Netherlands)

#90 Proteomics analysis shows that non-invasive epidermal sampling is a robust diagnostic approach for inflammatory skin diseases.
Anna Berekmeri (Leeds, United Kingdom)

#67 Major differences in expression of inflammatory products in skin from different body sites of healthy individuals.
Ester Del Duca (New York, USA)


#21 Sodium chloride is an ionic checkpoint for human Th2 cell responses and shapes the atopic skin micro environment
Christina Zielinski (Munich, Germany)




08.00 – 09.30 Atopic Dermatitis and Beyond: Pathogenic and Therapeutic Advances
Symposium supported by Sanofi Genzyme

Emma Guttman (New York, USA)

Atopic Dermatitis: Emerging as a cytokine-driven disease and novel therapeutic developments
Emma Guttman (New York, USA)

Pediatric atopic dermatitis–pathogenic and therapeutic advances and implications for the atopic march
Patrick Brunner (Vienna, Austria)

Th2 Inhibition beyond atopic dermatitis
Frank O. Nestle (Boston, USA)

Panel Discussion
Emma Guttman, Frank O. Nestle, Patrick Brunner

09.30 – 09.45   BREAK

Session chairs morning:
Amos Gilhar (Haifa, Israel)
Thomas Luger (Münster, Germany)

09.45 – 10.00 Oral presentations from selected abstracts

#120 Massive expansion of drug-specific, clonotypic and polycytotoxic CD8+ T cells in Toxic Epidermal Necrolysis.
Marc Vocanson (Lyon, France)

10.00  – 10.30   Alopecia areata
Ralf Paus (Manchester, UK)                                                          
10.30 – 11.00       Acne & Rosacea
Martin Steinhoff (Dublin, Ireland)
11.00 – 11.30     Vitiligo
John Harris (Worchester, MA, USA)
11.30  – 12.00    COFFEE BREAK
  Session chairs afternoon:
Peter Wolf (Graz, Austria)
Daniel Aletaha (Vienna, Austria)
12.00 – 12.30  Eosinophilic disorders
Bruce Bochner (Chicago, IL, USA)
12.30 – 13.00 Adding new pieces to the old Lupus puzzle
Virginia Pascual (New York, NY, USA)
13.00 – 13.30  Dermatomyositis: Pearls, Pitfalls, and an Evolving Therapeutic Landscape
Ruth Ann Vleugels (Boston, MA, USA)

Session chairs late afternoon:
Robert Bissonnette (Montreal, Canada)
Matthias Augustin (Hamburg, Germany)

13.30 – 14.20

Oral presentations from selected abstracts

#117 Early Improvement in Pruritus and Reduction in Clinical Signs in a Phase 2a Mechanism of Action Study of Crisaborole in Mild to Moderate Atopic Dermatitis.
Robert Bissonnette (Montreal, Canada)

#30 A Topical Nitric Oxide-Releasing Cream SB414: Results of a Phase 1b Double-Blind, Randomized, Vehicle-Controlled Study in Patients with Mild-to-Moderate Atopic Dermatitis.
Tomoko Maeda-Chubachi (Morrisville, USA)

#88 Topical DS107 for the treatment of mild-to-moderate Atopic Dermatitis: Results from ADVANTAGE, an 8 week phase 2b randomized, double-blind, vehicle-controlled study.
Moayed Hamza (Dublin, Ireland)

#103 Cerdulatinib (DMVT-502), a novel, topical dual Janus kinase/spleen tyrosine kinase inhibitor, improves the cellular and molecular cutaneous signature in patients with atopic dermatitis.
Anna Tallman (New York, USA)

14.20 – 14.30 Closing session